• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

晚期非小细胞肺癌患者的预后因素:单因素和多因素分析,包括递归划分与合并

Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation.

作者信息

Takigawa N, Segawa Y, Okahara M, Maeda Y, Takata I, Kataoka M, Fujii M

机构信息

Department of Medicine, National Shikoku Cancer Center Hospital, Matsuyama, Japan.

出版信息

Lung Cancer. 1996 Aug;15(1):67-77. doi: 10.1016/0169-5002(96)00571-5.

DOI:10.1016/0169-5002(96)00571-5
PMID:8865124
Abstract

In an attempt to determine the prognostic significance of pretreatment factors for patients with advanced non-small cell lung cancer (NSCLC), 24 pretreatment clinical variables were analyzed for 185 patients with NSCLC who underwent chemotherapy and/or radiotherapy between 1985 and 1994. Following univariate analysis, we applied two multivariate statistical techniques. In a Cox regression mode, independently significant factors influencing patient survival included performance status (PS), disease stage, hemoglobin level, and serum calcium level. Recursive partitioning and amalgamation (RPA) resulted in three distinct prognostic subgroups based on PS, stage, weight loss, and hemoglobin level. The best survival was observed for patients with a good PS and Stage III disease who had a hemoglobin level > 11 g/dl. The worst survival was observed for patients with a poor PS and presence of weight loss irrespective of stage. All other patients had an intermediate prognosis. Median survival times were 95.1 weeks, 17.1 weeks and 39.3 weeks, respectively (P < 0.00005). The results of our analyses show that three important prognostic subgroups could readily be discerned using RPA.

摘要

为了确定晚期非小细胞肺癌(NSCLC)患者预处理因素的预后意义,我们分析了1985年至1994年间接受化疗和/或放疗的185例NSCLC患者的24项预处理临床变量。单因素分析后,我们应用了两种多变量统计技术。在Cox回归模型中,影响患者生存的独立显著因素包括体能状态(PS)、疾病分期、血红蛋白水平和血清钙水平。递归分割合并法(RPA)根据PS、分期、体重减轻和血红蛋白水平得出了三个不同的预后亚组。PS良好且为Ⅲ期疾病、血红蛋白水平>11 g/dl的患者生存率最佳。PS差且存在体重减轻的患者,无论分期如何,生存率最差。所有其他患者预后中等。中位生存时间分别为95.1周、17.1周和39.3周(P<0.00005)。我们的分析结果表明,使用RPA可以很容易地识别出三个重要的预后亚组。

相似文献

1
Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation.晚期非小细胞肺癌患者的预后因素:单因素和多因素分析,包括递归划分与合并
Lung Cancer. 1996 Aug;15(1):67-77. doi: 10.1016/0169-5002(96)00571-5.
2
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.广泛期非小细胞肺癌的生存决定因素:西南肿瘤协作组的经验
J Clin Oncol. 1991 Sep;9(9):1618-26. doi: 10.1200/JCO.1991.9.9.1618.
3
Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.晚期非小细胞肺癌生存的预后因素:1052例患者的单因素和多因素分析,包括递归划分和合并算法。欧洲肺癌工作组。
J Clin Oncol. 1995 May;13(5):1221-30. doi: 10.1200/JCO.1995.13.5.1221.
4
Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival.对1999例局部晚期非小细胞肺癌(LA-NSCLC)患者进行递归分割分析:识别出五组具有不同生存率的患者。
Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1475-82. doi: 10.1016/s0360-3016(00)00801-4.
5
Prognostic factors in advanced non-small cell lung cancer: elevated serum levels of neuron specific enolase indicate poor prognosis.晚期非小细胞肺癌的预后因素:血清神经元特异性烯醇化酶水平升高提示预后不良。
Jpn J Clin Oncol. 2000 Dec;30(12):534-41. doi: 10.1093/jjco/hyd139.
6
Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy.对于接受化疗和放疗的Ⅲ期不可切除非小细胞肺癌,采用新的分期分类能更好地预测生存率。
Lung Cancer. 2004 Sep;45(3):339-48. doi: 10.1016/j.lungcan.2004.02.016.
7
Prognostic factors in older patients with advanced non-small cell lung cancer in China.中国老年晚期非小细胞肺癌患者的预后因素
Tumori. 2014 Jan-Feb;100(1):69-74. doi: 10.1700/1430.15818.
8
The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition.其他预后因素对生存的影响及其与《恶性肿瘤TNM分类》第6版所表达的疾病解剖范围的关系以及第7版的建议。
J Thorac Oncol. 2008 May;3(5):457-66. doi: 10.1097/JTO.0b013e31816de2b8.
9
Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.C反应蛋白和吸烟对接受一线姑息化疗的晚期非小细胞肺癌患者的预后意义
J Thorac Oncol. 2009 Mar;4(3):326-32. doi: 10.1097/JTO.0b013e31819578c8.
10
Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel.晚期非小细胞肺癌二线化疗的预后评分:比较长春氟宁与多西他赛的 III 期试验的外部验证。
Lung Cancer. 2012 Jul;77(1):116-20. doi: 10.1016/j.lungcan.2012.01.013. Epub 2012 Feb 21.

引用本文的文献

1
First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology.ECOG 体能状况 2 分的晚期非小细胞肺癌患者的一线免疫治疗:意大利胸部肿瘤学会国际专家小组会议的结果。
ESMO Open. 2022 Feb;7(1):100355. doi: 10.1016/j.esmoop.2021.100355. Epub 2021 Dec 16.
2
Prognostic Model to Predict Overall Survival for Metastatic Non-Small Cell Lung Cancer Patients Treated With Chemotherapy Combined With Concurrent Radiation Therapy to the Primary Tumor: Analysis From Two Prospective Studies.预测接受化疗联合原发肿瘤同步放疗的转移性非小细胞肺癌患者总生存期的预后模型:两项前瞻性研究的分析
Front Oncol. 2021 Feb 25;11:625688. doi: 10.3389/fonc.2021.625688. eCollection 2021.
3
Prognostic impact of maximum standardized uptake value on F-FDG PET/CT imaging of the primary lung lesion on survival in advanced non-small cell lung cancer: A retrospective study.最大标准化摄取值对晚期非小细胞肺癌原发肺病灶 F-FDG PET/CT 显像生存预后的影响:一项回顾性研究。
Thorac Cancer. 2021 Mar;12(6):845-853. doi: 10.1111/1759-7714.13863. Epub 2021 Jan 29.
4
Survival analysis and factors affecting survival in patients who presented to the medical oncology unit with non-small cell lung cancer.生存分析及影响非小细胞肺癌患者入医学肿瘤病房后生存的因素。
Turk J Med Sci. 2020 Dec 17;50(8):1838-1850. doi: 10.3906/sag-1912-205.
5
Preoperative anemia as a prognostic factor in patients with lung cancer: a systematic review and meta-analysis of epidemiological studies.术前贫血作为肺癌患者的一个预后因素:一项关于流行病学研究的系统评价和荟萃分析
J Cancer. 2019 May 12;10(9):2047-2056. doi: 10.7150/jca.29410. eCollection 2019.
6
The prognostic impact of decreased pretreatment haemoglobin level on the survival of patients with lung cancer: a systematic review and meta-analysis.治疗前血红蛋白水平降低对肺癌患者生存预后的影响:系统评价和荟萃分析。
BMC Cancer. 2018 Dec 10;18(1):1235. doi: 10.1186/s12885-018-5136-5.
7
Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review).培美曲塞用于体能状态为2的非小细胞肺癌患者的临床研究(综述)
Int J Oncol. 2016 Jan;48(1):13-27. doi: 10.3892/ijo.2015.3219. Epub 2015 Oct 29.
8
Inaugural bone metastases in non-small cell lung cancer: a specific prognostic entity?非小细胞肺癌的初发骨转移:一种特殊的预后实体?
BMC Cancer. 2014 Jun 10;14:416. doi: 10.1186/1471-2407-14-416.
9
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.一线接受厄洛替尼治疗的肺癌患者中 [18F]氟代胸腺嘧啶和 [18F]氟代-D-葡萄糖基线摄取的预后影响。
PLoS One. 2013;8(1):e53081. doi: 10.1371/journal.pone.0053081. Epub 2013 Jan 4.
10
Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies.外周血 CD8(+)T 细胞增殖与晚期胸部恶性肿瘤患者的预后相关。
Cancer Immunol Immunother. 2013 Mar;62(3):529-39. doi: 10.1007/s00262-012-1360-z. Epub 2012 Oct 16.